29 July 2006
Fish Oil Works Better Than Statins at Improving HDL Cholesterol
Dr. Joseph Mercola
A study has shown that fish oils are more effective than the statin drug Lipitor in positively affecting the levels of HDL ("good") cholesterol in obese and insulin-resistant men. HDL cholesterol protects against atherosclerosis by removing excess cholesterol from arterial cells, and low HDL levels can increase the risk of cardiovascular disease, particularly for those who are obese or insulin resistant.
In the six-week study, fish oils and Lipitor were given to 48 men, both separately and combined. Fish oil and Lipitor together greatly lowered plasma triacylglycerols and raised HDL cholesterol levels.
But only fish oil also influenced HDL cholesterol by altering the production and catabolism rates of HDL apolipoproteins (catabolism is the breakdown of complex molecules metabolically into simpler ones). Lipitor did not increase this effect when combined with the fish oils, and did not produce a similar effect on its own.
American Journal of Clinical Nutrition July 2006; 84(1): 37-43
18 July 2006
Resveratrol increases both average and maximum lifespan across a vast range of organisms. The largest recorded percentage increases are shown here. [Adapted from Baur JA, Sinclair DA. Therapeutic potential of resveratrol: the in vivo evidence. Nature Rev Drug Disc 2006 Jun;5(6):493-506.]
The evidence accumulating on resveratrol on life extension, cardiovascular and other positive effects is sufficient to recommend it as a regular supplement after Transfer Factor Plus and Dr. Sears Fish Oil. See Will Block. Resveratrol—Star Molecule Against Disease and Aging. Life Enhancement Foundation.
I've been taking this supplement for years and it may be one of the many factors that cause my biology age to be 24 years younger than my calendar age as tested by the Fronter Medical Clinic. I'm now recommending it to everyone.
15 July 2006
Vitamin C treatment shows cancer promise
As Sandy Kellar battles ovarian cancer, she’s noticing an unusual vitality in herself that she doesn’t see in others with the disease.
“I can be a grandma and play with those grandkids in the backyard and anything I want,” the Overland Park resident said.
Kellar attributes her energy to her twice-weekly intravenous vitamin C treatments, a therapy that is gaining followers and spurring new research, including a trial at Kansas University Medical Center.
Jeanne Drisko, medical director for the KU Medical Center’s Program in Integrative Medicine, is in the process of completing a multiyear, $375,000 trial of intravenous vitamin C in ovarian cancer patients. The study is funded by the Cancer Treatment Research Foundation, a nonprofit agency based in Schaumburg, Ill.
The study began in 2002 and enrolled its last patient in 2005. Women in the trial were given doses of vitamin C intravenously twice a week while also undergoing conventional chemotherapy treatment. Drisko declined to discuss the results until the trial is complete, but she said the therapy is safe.
“We haven’t had any adverse events,” she said. “We’re encouraged enough that we’re continuing.”
Once championed by Nobel Laureate Linus Pauling, vitamin C as a cancer treatment suffered a setback in the 1970s when the Mayo Clinic studied orally ingested vitamin C pills and found no effect on cancer patients, Drisko said.
“Everyone thought, ‘This is the definitive study,’” she said of the Mayo Clinic’s research.
But vitamin C pills are different from intravenous vitamin C.
“When you give it by vein, it’s like a drug,” Drisko said. “When you give it by mouth, it’s just a vitamin.”
11 July 2006
A University of Utah study showed that motorists who talked on either handheld or hands-free phones:
- drove slightly slower
- were 9% slower to hit brakes
- showed 24% more variation in following distance
- 19% slower to resume normal speed after braking
- more likely to crash
Marginal drunks with a 0.08 blood-alcohol level:
- drove more slowly yet more aggressively than either normal drivers or cell-phone users
- followed more closely
- twice as likely to brake 4 seconds before a collision would have occurred
- hit their brakes with 23% more force
- accident rates did not differ from normal drivers
About 8% of drivers are talking on cell-phones which is much higher than the drunk driver rate. That means you are more likely to be injured by a cell-phone user than a drunk.
"We found that people are as impaired when they drive and talk on a cell phone as they are when they drive intoxicated at the legal blood-alcohol limit of 0.08 percent, which is the minimum level that defines illegal drunken driving in most U.S. states," says study co-author Frank Drews, an assistant professor of psychology. “If legislators really want to address driver distraction, then they should consider outlawing cell phone use while driving.”
A Comparison of the Cell Phone Driver and the Drunk Driver
David L. Strayer, Frank A. Drews, and Dennis J. Crouch
University of Utah, Salt Lake City, Utah
Human Factors: The Journal of the Human Factors and Ergonomics Society, Summer 2006
Influenza Vaccination During Pregnancy: A Critical Assessment of the Recommendations of the Advisory Committee on Immunization Practices (ACIP)
David M. Ayoub, M.D. and F. Edward Yazbak, M.D
Journal of American Physicians and Surgeons 11:2, Summer 2006
Influenza vaccination during all trimesters of pregnancy is now universally recommended in the United States. We critically reviewed the influenza vaccination policy of the CDC's Advisory Committee on Immunization Practice (ACIP) and the citations that were used to support their recommendations.
The ACIP's citations and the current literature indicate that influenza infection is rarely a threat to a normal pregnancy. There is no convincing evidence of the effectiveness of influenza vaccination during this critical period. No studies have adequately assessed the risk of influenza vaccination during pregnancy, and animal safety testing is lacking. Thimerosal, a mercury-based preservative present in most inactivated formulations of the vaccine, has been implicated in human neurodevelopment disorders, including autism, and a broad range of animal and experimental reproductive toxicities including teratogenicity, mutagenicity, and fetal death. Thimerosal is classified as a human teratogen.
The ACIP policy recommendation of routinely administering influenza vaccine during pregnancy is ill-advised and unsupported by current scientific literature, and it should be withdrawn. Use of thimerosal during pregnancy should be contraindicated.
Adverse Cardiovascular Effects of Rofecoxib
Steven E. Nissen, M.D., Cleveland Clinic Foundation
New England Journal of Medicine 355;2 - July 13, 2006
The recent public disclosure of data from a 12-month extension study of the Adenomatous Polyp Prevention on Vioxx (APPROVe) trial provides new insights into the effect of rofecoxib on cardiovascular events. These new data reveal the full results of both the original study and the extension phase, including data tables and Kaplan–Meier curves. In the original article, the APPROVe investigators reported event rates using an unusual censoring rule in which events were excluded if they occurred more than 14 days after the study drug was stopped. All data in the new report are assessed by a conventional intention-to-treat analysis. This new report also provides analysis that uses several different end points, including the widely used end point of the Antiplatelet Trialists’ Collaboration (APTC) study. The original article included a post hoc hypothesis that curves for confirmed thrombotic events would not begin to diverge until after 18 months of exposure to rofecoxib. However, all intention-to-treat analyses in the newly released report show that the event curves begin to diverge much earlier, generally within four to six months.
07 July 2006
Sundaram M, Guernsey DL, Rajaraman MM, Rajaraman R.
Cancer Biol Ther. 2004 Feb;3(2):207-18. Epub 2004 Feb 1.Department of Medicine and Microbiology and Immunology,
Using computerized video time-lapse microscopy, we studied early cellular events during carcinogen-induced transformation of C3H10T1/2 cells. Multinucleate/polyploid giant cells (MN/PGs) formed due to